

OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE  
SECRETARY OF STATE

CHERYL MYERS  
DEPUTY SECRETARY OF STATE  
AND TRIBAL LIAISON



ARCHIVES DIVISION

STEPHANIE CLARK  
DIRECTOR

800 SUMMER STREET NE  
SALEM, OR 97310  
503-373-0701

**NOTICE OF PROPOSED RULEMAKING**  
INCLUDING STATEMENT OF NEED & FISCAL IMPACT

CHAPTER 855  
BOARD OF PHARMACY

**FILED**

04/17/2024 10:12 AM  
ARCHIVES DIVISION  
SECRETARY OF STATE

FILING CAPTION: Repeals Div 020 Protocol Compendium

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 05/22/2024 4:30 PM

*The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.*

CONTACT: Rachel Melvin  
971-673-0001  
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150  
Portland, OR 97232

Filed By:  
Rachel Melvin  
Rules Coordinator

HEARING(S)

*Auxiliary aids for persons with disabilities are available upon advance request. Notify the contact listed above.*

DATE: 05/22/2024

TIME: 9:30 AM

OFFICER: Rachel Melvin

REMOTE HEARING DETAILS

MEETING URL: [Click here to join the meeting](#)

PHONE NUMBER: 503-446-4951

CONFERENCE ID: 392711816

SPECIAL INSTRUCTIONS:

This hearing meeting will be held virtually via Microsoft Teams.

If you wish to present oral testimony virtually during this hearing, sign up on our website at [www.oregon.gov/pharmacy/pages/rulemaking-information](http://www.oregon.gov/pharmacy/pages/rulemaking-information) or email your first and last name and email address to

[pharmacy.rulemaking@bop.oregon.gov](mailto:pharmacy.rulemaking@bop.oregon.gov) to receive a calendar invitation to join the virtual hearing. Please indicate which

rule(s) you would like to comment on.

You must submit written comments before 4:30PM on May 22, 2024. Email written comments to [pharmacy.rulemaking@bop.oregon.gov](mailto:pharmacy.rulemaking@bop.oregon.gov).

NEED FOR THE RULE(S)

Proposes to permanently repeal OAR 855-020-0300 Protocol Compendium which is now located in OAR 855-115-0345.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE

OAR 855-115-0345 <https://secure.sos.state.or.us/oard/viewSingleRule.action?ruleVrsnRsn=311546>

STATEMENT IDENTIFYING HOW ADOPTION OF RULE(S) WILL AFFECT RACIAL EQUITY IN THIS STATE

The proposed rule repeal is not expected to affect racial equity in this state.

FISCAL AND ECONOMIC IMPACT:

The proposed rule repeal has no anticipated fiscal and economic impact.

COST OF COMPLIANCE:

(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).

The proposed rule repeal will have no additional economic impact on state agencies, units of local government, the public or registrants or licensees who identify as a small business.

DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

Small businesses were not involved in determining to repeal the rule. A notice of rulemaking hearing will be sent to interested parties, some of whom may identify as a small business and will have an opportunity to provide public comment on the proposed rule repeal.

WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?

No. The board adopted new Division 115 Pharmacists rules effective 3/1/2024. The nature of the proposed rule repeal does not require input from an advisory committee.

REPEAL: 855-020-0300

RULE SUMMARY: Permanently repeals OAR 855-020-0300 Protocol Compendium. The board adopted Division 115 Pharmacists rules effective 3/1/2024 which replace Division 020. OAR 855-115-0345 includes current versions of the protocols.

CHANGES TO RULE:

~~855-020-0300~~

~~Protocol Compendium~~

~~A Pharmacist may prescribe, via statewide drug therapy management protocol and according to rules outlined in this Division, an FDA-approved drug and device listed in the following compendium:~~

~~(1) Continuation of therapy including emergency refills of insulin (v. 06/2023);~~

~~(2) Conditions~~

~~(a) Cough and cold symptom management~~

~~(A) Pseudoephedrine (v. 06/2021);~~

~~(B) Benzonatate (v. 06/2021);~~

~~(C) Short-acting beta agonists (v. 06/2021);~~

~~(D) Intranasal corticosteroids (v. 06/2021);~~

~~(b) Vulvovaginal candidiasis (VVC) (v. 06/2021);~~

~~(c) COVID-19 Antigen Self-Test (v. 12/2021);~~

~~(3) Preventative care~~

~~(a) Emergency Contraception (v. 06/2021);~~

~~(b) Male and female condoms (v. 06/2021);~~

~~(c) Tobacco Cessation, Nicotine Replacement Therapy (NRT) and Non-NRT (v. 06/2022);~~

~~(d) Travel Medications (v. 06/2023);~~

~~(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);~~

~~(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 06/2023);~~

- (g) Contraception (v. 06/2023); and ¶
  - (h) Vaccinations: ¶
  - (A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 2/2024); ¶
  - (B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 2/2024); ¶
  - (C) Cholera (v. 2/2024); ¶
  - (D) Coronavirus 2019 (v. 2/2024); ¶
  - (E) Haemophilus Influenza type b (v. 2/2024) ¶
  - (F) Hepatitis A containing vaccines (v. 2/2024); ¶
  - (G) Hepatitis B containing vaccines (v. 2/2024); ¶
  - (H) Human Papillomavirus (v. 2/2024); ¶
  - (I) Influenza – Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2023-24 (v. 2/2024); ¶
  - (J) Influenza – Live Attenuated Influenza Vaccine 2023-24 (v. 2/2024); ¶
  - (K) Japanese Encephalitis (v. 2/2024); ¶
  - (L) Meningococcal containing vaccines (v. 2/2024); ¶
  - (M) Measles Mumps & Rubella containing vaccines (v. 2/2024); ¶
  - (N) Pneumococcal (v. 2/2024); ¶
  - (O) Polio (v. 2/2024); ¶
  - (P) Rabies (v. 2/2024); ¶
  - (Q) Respiratory Syncytial Virus (v. 2/2024); ¶
  - (R) Tetanus Diphtheria containing vaccines (v. 2/2024); ¶
  - (S) Typhoid (v. 2/2024); ¶
  - (T) Varicella containing vaccines (v. 2/2024); ¶
  - (U) Yellow fever (v. 2/2024); ¶
  - (V) Zoster (v. 2/2024). ¶
- [Publications referenced are available from the agency.]  
Statutory/Other Authority: ORS 689.205  
Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.696